Estudo unicêntrico, multicêntrico, que avalia a aceitação e viabilidade de uma ferramenta digital de monitorização remota configurada para pacientes com ATTR-CM: ACO-Monitor (ACO-MONITOR)
Um Estudo Observacional para Saber Mais Sobre o Quão Aceitável e Prático é uma Ferramenta Digital de Monitorização Remota (Luscii) em Pessoas com Cardiomiopatia Amilóide por Transtirretina (ATTR-CM)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This build-up makes the heart stiff and can lead to symptoms of heart failure, such as difficulty breathing, tiredness, swelling in the legs, and reduced ability to be physically active. ATTR-CM occurs in two forms: a hereditary (variant) type caused by changes in genes, and a wild-type form that usually develops with aging.
People living with ATTR-CM are usually cared for at specialist centers, which may require them to travel long distances for appointments. Because of this, visits may be infrequent, and sometimes people only see their doctor once a year. This can make it harder to notice if the disease is getting worse or if there are problems with following their treatment plan. As a result, important changes in health may go unnoticed for several months, which can be risky.
Remote monitoring offers a way for people living with ATTR-CM and their healthcare professionals to stay connected between clinic visits. Recent studies have shown that remote monitoring can help by making it easier to share health information, spot problems earlier, and support people to follow their treatment plans. This can lead to fewer hospital visits and better health outcomes.
Luscii is a digital remote monitoring tool designed to help people living with ATTR-CM and their healthcare professionals stay connected between clinic visits. Luscii has two main parts: Luscii contact, a smartphone app that allows secure messaging and video calls, and Luscii vitals, a clinical software system that organizes health data and can alert the healthcare team if there are changes that need attention. Luscii vitals is a CE-marked medical device used within its approved purpose and does not replace a doctor's judgement.
By making it easier to communicate and share information, Luscii aims to support earlier detection of problems, better management of ATTR-CM, and a more positive experience for people living with this condition.
The main purpose of this observational study, called ACO-MONITOR, is to learn how acceptable and practical Luscii is for people living with ATTR-CM and their healthcare professionals. The study will take place in Austria, Germany, and Italy at three specialist centers. About 60 adults with a diagnosis of hereditary or wild-type ATTR-CM will be invited to take part. There will be no treatments given as part of this study. Instead, participants will use the Luscii app and devices at home to track their health and share information with their healthcare professionals. The study team will provide training on how to use Luscii and will help participants get started.
The study team will look at:
- How quickly and how often participants and healthcare professionals use Luscii
- How long Luscii is used by each person
- How many times participants use Luscii after being reminded
- How easy Luscii is to use, based on questionnaires for both participants and healthcare professionals
The study will last about 18 months in total, including a 6-month period to invite participants and a 12-month follow-up period. During the study, the study team will:
- Support participants in using Luscii to share health information from home
- Monitor how often and how easily Luscii is used
- Ask participants and healthcare professionals about their experiences using Luscii, including what worked well and what could be improved
- Record any problems or technical issues with using Luscii By collecting this information, the researchers hope to learn if Luscii can help improve communication, support earlier detection of health problems, and make it easier for people living with ATTR-CM to manage their condition between clinic visits.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Bayer Clinical Trials Contact
- Número de telefone: (+)1-888-84 22937
- E-mail: clinical-trials-contact@bayer.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Eligible participants will be invited by their treating physician and, after providing informed consent, will be observed for approx. 12 months. Patients with an established diagnosis of either wild-type or variant ATTR-CM can be enrolled. Evidence of assessment of all eligibility criteria by the physician or a delegate, as well as enrolment of a participant in the study should be documented in the participant medical records. Medical professionals who are directly involved in the participants' treatment and who have access to and will review the Luscii-captured data for routine care are asked to complete the study-specific questionnaires/forms.
Descrição
Inclusion Criteria:
For patients:
- Adult (≥18 years at the date of signing the informed consent form (ICF)).
- Diagnosis of either wild-type or variant ATTR-CM.
- Treatment with a drug approved for ATTR-CM, including newly prescribed therapy at the initial visit.
- Signed ICF.
- Access to and basic ability to use a personal smartphone with internet connectivity sufficient to install and operate the Luscii contact application.
For medical professionals:
- Directly involved in the treatment or clinical management of the enrolled ATTR-CM participants and having access to and reviewing the Luscii-captured data for routine care.
- Agreement to ICF within the EDC system for the purpose of using Luscii or to complete the HCP Experience Questionnaire.
Exclusion Criteria:
For patients:
- Participation in an investigational program with interventions outside of routine clinical practice.
- Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.
For medical professionals:
- Any current affiliation with Luscii, Bayer, or any of their affiliates.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Wild-type or variant ATTR-CM participants
Participants will be enrolled after the decision to initiate the use of the digital remote monitoring tool, Luscii, as per standard use. |
The Luscii tool (CE class IIa certification) will be utilized for remote monitoring of health data specific to ATTR-CM patients. Following the observational nature of the study, no additional interventions will be implemented beyond the standard use of the Luscii tool. Participants will use the Luscii tool continuously throughout the observational period, which is approximately 12 months. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Acceptance of Luscii among medical professionals
Prazo: At baseline (initial visit), at 6 months and at 12 months
|
Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii vitals and Luscii contact throughout the study period. |
At baseline (initial visit), at 6 months and at 12 months
|
|
Acceptance of Luscii among participants with ATTR-CM
Prazo: At baseline (initial visit), at 6 months and at 12 months
|
Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii contact throughout the observational period. |
At baseline (initial visit), at 6 months and at 12 months
|
|
Feasibility of Luscii for medical professionals
Prazo: At baseline (initial visit), at 6 months and at 12 months
|
Defined as the practicality of implementing the tool in real-world ATTR-CM care throughout the study period. |
At baseline (initial visit), at 6 months and at 12 months
|
|
Feasibility of Luscii for participants with ATTR-CM
Prazo: At baseline (initial visit), at 6 months and at 12 months
|
Defined as the practicality of using the tool in real-world settings throughout the observational period. |
At baseline (initial visit), at 6 months and at 12 months
|
|
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among participants
Prazo: At baseline (initial visit), at 6 months and at 12 months
|
Measured by the Patient Experience Questionnaire |
At baseline (initial visit), at 6 months and at 12 months
|
|
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among medical professionals
Prazo: At baseline (initial visit), at 6 months and at 12 months
|
Measured by the Healthcare Professional (HCP) Experience Questionnaire |
At baseline (initial visit), at 6 months and at 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Número de doentes que falharam no rastreio
Prazo: Na visita inicial (consulta inicial)
|
Na visita inicial (consulta inicial)
|
|
|
Razão para a falha na triagem
Prazo: Na consulta inicial (visita inicial)
|
Na consulta inicial (visita inicial)
|
|
|
Participant demographic characteristics: age
Prazo: At baseline (initial visit)
|
Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline (initial visit) |
At baseline (initial visit)
|
|
Participant demographic characteristics: sex
Prazo: At baseline (initial visit)
|
Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline |
At baseline (initial visit)
|
|
Participant demographic characteristics: race
Prazo: At baseline (initial visit)
|
Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline |
At baseline (initial visit)
|
|
Clinical characteristics: National Amyloidosis Centre (NAC) Stage
Prazo: At baseline (initial visit)
|
Categorization of participants according to the NAC Stage into stages I, II, or III, with stage III indicating a higher risk of mortality |
At baseline (initial visit)
|
|
Clinical characteristics: relevant comorbidities
Prazo: At baseline (initial visit)
|
ATTR-CM relevant comorbidities |
At baseline (initial visit)
|
|
Treatment patterns with Acoramidis: ATTR-CM prior medications
Prazo: At baseline (initial visit)
|
Concomitant medications administered within the past 12 months before initial visit |
At baseline (initial visit)
|
|
Treatment patterns with Acoramidis: ATTR-CM concomitant medications
Prazo: At baseline (initial visit)
|
Previously administered ATTR-CM related medications within the past 12 months before initial visit |
At baseline (initial visit)
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 23127
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .